BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 14,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $19.43, for a total transaction of $272,020.00. Following the transaction, the chief executive officer now directly owns 189,014 shares of the company’s stock, valued at approximately $3,672,542.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Michael Rice also recently made the following trade(s):

  • On Wednesday, September 11th, Michael Rice sold 14,571 shares of BioLife Solutions stock. The stock was sold at an average price of $19.36, for a total value of $282,094.56.
  • On Thursday, August 15th, Michael Rice sold 9,905 shares of BioLife Solutions stock. The stock was sold at an average price of $18.07, for a total value of $178,983.35.
  • On Tuesday, August 13th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The shares were sold at an average price of $17.07, for a total value of $153,630.00.
  • On Tuesday, July 16th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The shares were sold at an average price of $16.29, for a total value of $146,610.00.
  • On Thursday, July 18th, Michael Rice sold 18,903 shares of BioLife Solutions stock. The shares were sold at an average price of $16.29, for a total value of $307,929.87.
  • On Thursday, June 13th, Michael Rice sold 18,903 shares of BioLife Solutions stock. The stock was sold at an average price of $17.37, for a total value of $328,345.11.

Shares of BioLife Solutions stock traded down $0.52 on Wednesday, reaching $19.09. The company’s stock had a trading volume of 139,842 shares, compared to its average volume of 172,177. The company has a market capitalization of $362.77 million, a price-to-earnings ratio of 136.36 and a beta of 1.43. The firm’s fifty day simple moving average is $19.19 and its two-hundred day simple moving average is $17.93. BioLife Solutions Inc has a 52 week low of $9.15 and a 52 week high of $22.44. The company has a quick ratio of 7.71, a current ratio of 9.42 and a debt-to-equity ratio of 0.02.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. BioLife Solutions had a return on equity of 8.65% and a net margin of 14.60%. The firm had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $6.59 million. As a group, research analysts predict that BioLife Solutions Inc will post 0.08 EPS for the current year.

Several equities analysts have recently weighed in on BLFS shares. ValuEngine downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Northland Securities upped their price target on shares of BioLife Solutions from $18.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. HC Wainwright started coverage on shares of BioLife Solutions in a research note on Monday, July 22nd. They issued a “buy” rating and a $23.00 price target on the stock. Zacks Investment Research downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, Maxim Group set a $24.00 price objective on shares of BioLife Solutions and gave the company a “buy” rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $19.33.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC lifted its stake in BioLife Solutions by 2.9% in the first quarter. Janney Montgomery Scott LLC now owns 21,115 shares of the medical equipment provider’s stock worth $378,000 after acquiring an additional 600 shares during the last quarter. Morgan Stanley raised its position in shares of BioLife Solutions by 17.5% during the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after acquiring an additional 1,713 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of BioLife Solutions during the 2nd quarter worth about $30,000. Cadence Capital Management LLC lifted its stake in BioLife Solutions by 1.8% during the first quarter. Cadence Capital Management LLC now owns 195,269 shares of the medical equipment provider’s stock worth $3,493,000 after purchasing an additional 3,439 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in BioLife Solutions by 4.7% during the second quarter. Invesco Ltd. now owns 81,319 shares of the medical equipment provider’s stock worth $1,378,000 after purchasing an additional 3,669 shares during the last quarter. Institutional investors and hedge funds own 48.44% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Read More: Trading signals using Bollinger bands

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.